FDA Approves Afstyla (Antihemophilic Factor (Recombinant), Single Chain) for Hemophilia A

KING OF PRUSSIA, Pa. — 26 May 2016 -- CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has approved Afstyla [Antihemophilic Factor (Recombinant), Single Chain], its novel long-lasting recombinant factor VIII...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news